Interim report January - March 2020
Gothenburg, May 5, 2020 - Vicore Pharma Holding AB (publ) publishes the interim report for the first quarter 2020.Important events during the first quarter · In January, Vicore issued 243,525 shares to the warrant holders in the incentive programme LTIP 2016. · In the beginning of 2020, the phase II study with C21 in patients with systemic sclerosis (SSc) and Raynaud's phenomenon dosed its first patients. · In March, Vicore submitted a Clinical Trial Application (CTA) to the UK regulatory agency MHRA, for a phase II study with C21 in patients with IPF. The study has been re-